Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $51
Harmony Biosciences Holdings Inc HRMY
$35.24
▼ -1.73%
($-0.62)
📅 Earnings This Week
Open
$35.86
Prev Close
$35.86
Day Range
$34.58 – $35.87
52W Range
$25.52 – $40.87
Market Cap
$2.04B
P/E (TTM)
14.01
Beta
0.92
EPS (TTM)
$2.49
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-08-19 |
| Shares Out. | 57,890,000 |
| Website | harmonybiosciences.com/ ↗ |
| Phone | 13026587581 |
| Employees | 293 |
| Revenue | $215.4M |
| Gross Profit | $170.9M |
| Net Income | $32.5M |
| Free Cash Flow | $341.8M |
| Total Assets | $1.27B |
| Total Liabilities | $361.5M |
| Equity | $910.3M |
About Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Harmony Biosciences Holdings Inc is a publicly traded company under the ticker symbol HRMY on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)